Coverage
-
February 25, 2019
A Third Circuit panel on Monday rejected the Federal Trade Commission's bid to revive its suit accusing a Shire PLC unit of delaying generic competition for a gastrointestinal infection drug several years ago through sham regulatory filings, saying the agency can't challenge purely past conduct in federal courts.
6 other articles on this case.
View all »